The following table presents revenue by category:


	Year Ended March 31,
	2023					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
Point in Time
PGS	$	182,866		61	%	$	189,703		70	%	$	191,066		78	%
Telehealth		34,961		12	%		15,299		6	%		—		0	%
Consumer services		217,827		73	%		205,002		76	%		191,066		78	%
Research services		—		0	%		—		0	%		—		0	%
Therapeutics		—		0	%		—		0	%		54		0	%
Total	$	217,827		73	%	$	205,002		76	%	$	191,120		78	%

Over Time
PGS	$	19,548		7	%	$	12,978		5	%	$	6,459		3	%
Telehealth		9,761		3	%		3,908		1	%		—		0	%
Consumer services		29,309		10	%		16,886		6	%		6,459		3	%
Research services		52,353		17	%		50,005		18	%		46,341		19	%
Therapeutics		—		0	%		—		0	%		—		0	%
Total	$	81,662		27	%	$	66,891		24	%	$	52,800		22	%

Revenue by Category
PGS	$	202,414		68	%	$	202,681		75	%	$	197,525		81	%
Telehealth		44,722		15	%		19,207		7	%		—		0	%
Consumer services		247,136		83	%		221,888		82	%		197,525		81	%
Research services		52,353		17	%		50,005		18	%		46,341		19	%
Therapeutics		—		0	%		—		0	%		54		0	%
Total	$	299,489		100	%	$	271,893		100	%	$	243,920		100	%

The following table summarizes revenue by region based on the shipping address of customers or the location where the services are delivered:


	Year Ended March 31,
	2023					2022					2021
	Amount		% of Revenue			Amount		% of Revenue			Amount		% of Revenue
	(in thousands, except percentages)
United States	$	217,242		73	%	$	192,438		71	%	$	176,120		72	%
United Kingdom		63,023		21	%		58,477		22	%		49,386		20	%
Canada		13,581		4	%		14,293		5	%		12,172		5	%
Other regions		5,643		2	%		6,685		2	%		6,242		3	%
Total	$	299,489		100	%	$	271,893		100	%	$	243,920		100	%

Accounts receivable are recorded when the right to consideration becomes unconditional. Contract assets include amounts associated with contractual rights related to consideration for performance obligations and are included in prepaid expenses and other current assets on the consolidated balance sheets. The amount of contract assets was immaterial as of March 31, 2023 and 2022.

Contract liabilities consist of deferred revenue. Revenue is deferred when the Company invoices in advance of fulfilling performance obligations under a contract. Deferred revenue primarily relates to Kits that have been shipped to consumers and non-consigned retail sites but not yet returned for processing by the consumer, as well as research services billed in advance of performance. Deferred revenue is recognized when the obligation to deliver results to the customer is satisfied and when research services are ultimately performed. Deferred revenue also consists of advance payments from members related to membership performance obligations and from customers related to subscription for extended health insight performance obligations that have not been satisfied as of the balance sheet date. Deferred revenue is recognized when the obligation to deliver membership services or subscription services is satisfied.

As of March 31, 2023 and 2022, deferred revenue for consumer services was $48.6 million and $51.3 million, respectively. Of the $51.3 million and $39.3 million of deferred revenue for consumer services as of March 31, 2022 and 2021, respectively, the Company recognized $46.6 million and $31.9 million as revenue during the fiscal years ended March 31, 2023 and 2022, respectively.

As of March 31, 2023 and 2022, deferred revenue for research services was $14.0 million and $11.6 million, respectively, which included related party deferred revenue amounts of $11.8 million and $9.2 million, respectively. Of the $11.6 million and $31.9 million of deferred revenue for research services as of March 31, 2022 and 2021, respectively, the Company recognized $9.7 million and $31.4 million as revenue during the fiscal years ended March 31, 2023 and 2022, respectively, which included related party revenue amounts of $9.2 million and $30.1 million, respectively.

The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that are expected to be billed and recognized as revenue in future periods. The Company has utilized the practical expedient available under ASC 606 to not disclose the value of unsatisfied performance obligations for PGS and telehealth as those contracts have an expected length of one year or less. As of March 31, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations for research services was $21.6 million. The Company expects to recognize revenue on approximately 91% of this amount over the next 12 months and the remainder thereafter. During the fiscal years ended March 31, 2023, 2022 and 2021, the Company did not recognize any revenue for performance obligations satisfied in prior periods.